Caley Castelein
CIK: 0001355758
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 12, 2026WHWK
Whitehawk Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
38K shares- - May 14, 2026WHWK
Whitehawk Therapeutics, Inc.
Award(A)Direct255.1K shares at avg. $3.92$1000K - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Disposition(D)DirectEmployee Stock Option (Right to Buy)
10K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Tender Offer(U)Indirect431.9K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Disposition(D)DirectEmployee Stock Option (Right to Buy)
10K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Tender Offer(U)Direct516K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Disposition(D)DirectEmployee Stock Option (Right to Buy)
16.8K shares- - Oct 15, 2025TRML
Tourmaline Bio, Inc.
Gift(G)Direct522 shares- - Jun 12, 2025WHWK
Whitehawk Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
40K shares- - Jun 4, 2025TRML
Tourmaline Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
16.8K shares- - Mar 4, 2025AADI
Aadi Bioscience, Inc.
Award(A)Indirect1.7M shares at avg. $2.40$4.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  WHWK Whitehawk Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 38,040 | - | - | Direct |
| May 14, 2026 | WHWK Whitehawk Therapeutics, Inc. | Award(A) | 255,102 | $3.92 | $1,000,000 | Direct |
| Oct 28, 2025 |  TRML Tourmaline Bio, Inc. | Disposition(D) Employee Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Tender Offer(U) | 431,939 | - | - | Indirect |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Disposition(D) Employee Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Tender Offer(U) | 515,997 | - | - | Direct |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Disposition(D) Employee Stock Option (Right to Buy) | 16,800 | - | - | Direct |
| Oct 15, 2025 | TRML Tourmaline Bio, Inc. | Gift(G) | 522 | - | - | Direct |
| Jun 12, 2025 | WHWK Whitehawk Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 40,006 | - | - | Direct |
| Jun 4, 2025 | TRML Tourmaline Bio, Inc. | Award(A) Stock Option (Right to Buy) | 16,800 | - | - | Direct |
| Mar 4, 2025 |  AADI Aadi Bioscience, Inc. | Award(A) | 1,666,000 | $2.40 | $3,998,400 | Indirect |
1-11 of 11 transactions
About Castelein Caley
Castelein Caley (SEC CIK 0001355758) files insider reports with the SEC as Director of Whitehawk Therapeutics, Inc. (WHWK) and Director of Tourmaline Bio, Inc. (TRML).
Signal8 holds 7 ownership filings by Castelein Caley, all Form 4s, filed between Mar 4, 2025 and Jun 15, 2026. Those filings report 11 transactions, from Mar 4, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Castelein Caley's filings is in MORRISTOWN, NJ.
Recent filings by Castelein Caley
- Jun 12, 2026: Grant or award of WHWK derivative securities (Form 4, code A).
- May 14, 2026: Grant or award of WHWK shares (Form 4, code A).
- Oct 28, 2025: Disposition to issuer transaction of TRML derivative securities (Form 4, code D).
- Oct 28, 2025: Tender of shares transaction of TRML shares (Form 4, code U).
- Oct 28, 2025: Disposition to issuer transaction of TRML derivative securities (Form 4, code D).
Other insiders filing for Whitehawk Therapeutics, Inc. (WHWK)
- Giacobello Scott M., CHIEF FINANCIAL OFFICER
- BALL BRYAN
- Dornan David, Chief Scientific Officer
- Lennon David James, CHIEF EXECUTIVE OFFICER
- Dugan Margaret, Chief Medical Officer
- Iyengar Vijay K, Director